Can ropinirole (Requip) be used to treat restless‑legs syndrome during opioid detoxification?

Ropinirole for RLS During Opioid Detox

Ropinirole can be used to treat RLS during opioid detoxification, but it should not be your first-line choice—prioritize gabapentin, pregabalin, or gabapentin enacarbil instead, as these are strongly recommended for RLS and carry lower risk of augmentation, which is particularly important given the already complex withdrawal scenario.

Evidence-Based Rationale

Current Guideline Position on Ropinirole

The 2025 AASM guidelines explicitly suggest against the standard use of ropinirole for RLS (conditional recommendation, moderate certainty of evidence) 1. However, the guidelines acknowledge that ropinirole may be used in patients who place higher value on short-term symptom reduction and lower value on long-term adverse effects, particularly augmentation 1.

Why This Matters During Detox

RLS is highly prevalent during opioid withdrawal—occurring in approximately 50.8% of patients undergoing opioid detoxification 2. This is more than twice the rate seen in alcohol detoxification (21.7%) 2. The mechanism appears related to dopaminergic dysregulation during withdrawal 3.

Preferred Treatment Algorithm for RLS During Detox

First-line options (Strong recommendations):

• Gabapentin (strong recommendation, moderate certainty) 1
• Pregabalin (strong recommendation, moderate certainty) 1
• Gabapentin enacarbil (strong recommendation, moderate certainty) 1

These alpha-2-delta ligands are superior choices because:

• They have strong evidence for efficacy
• Lower augmentation risk compared to dopamine agonists 4
• No abuse potential concerns in this vulnerable population
• Better long-term safety profile

Second-line option:

• Ropinirole 0.25-4.0 mg once daily, 1-3 hours before bedtime 5

If You Choose Ropinirole

Dosing specifics from FDA labeling:

• Start at 0.25 mg once daily 5
• Titrate based on response and tolerability
• Take 1-3 hours before bedtime 5
• Reaches peak concentration in 1-2 hours 5

Critical monitoring requirements:

• Orthostatic hypotension (especially during dose escalation—common in detox patients already at risk) 5
• Augmentation (worsening of RLS symptoms with earlier onset, shorter latency, or spread to other body parts)—this is the primary long-term concern 1
• Impulse control disorders (particularly problematic in substance use disorder population) 1
• Nausea and dizziness (most common adverse effects) 6, 7

Evidence Supporting Ropinirole Efficacy

While ropinirole is effective for RLS symptom reduction:

• Significant IRLS score improvements versus placebo (mean difference -3.01 to -3.7 points) 7, 8
• Benefits apparent within 1-2 weeks 6, 7
• Improves subjective sleep measures 9, 7
• Case reports specifically document successful use during opioid withdrawal 3

However, the 2018 evidence review identified augmentation as occurring more frequently with dopaminergic agents (including ropinirole) compared to alpha-2-delta ligands 4.

Common Pitfalls to Avoid

1. Don't use ropinirole as first-line when gabapentin/pregabalin are available and appropriate
2. Don't ignore iron status—check ferritin and consider IV ferric carboxymaltose if ferritin <200 ng/mL with transferrin saturation <20% (strong recommendation) 1
3. Don't overlook augmentation monitoring—this requires specific questioning about symptom timing, severity, and body distribution
4. Don't combine with other dopaminergic agents during the detox period
5. Don't forget orthostatic precautions—patients in detox are already volume-depleted and autonomically unstable

Practical Clinical Approach

Start with gabapentin 300 mg at bedtime, titrate to effect (up to 1800-2400 mg/day in divided doses). If gabapentin fails or is contraindicated, then consider ropinirole 0.25 mg at bedtime with careful titration and monitoring for augmentation and orthostatic symptoms.